Rui Avelar - 17 Feb 2026 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role: Chief Medical Officer and Head of R&D
Signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol: EOLS
Transactions as of: 17 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 19 Feb 2026, 20:57:17 UTC
Previous filing: 29 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Avelar Rui	Chief Medical Officer and Head of R&D	520 NEWPORT CENTER DR., SUITE 1200, NEWPORT BEACH	/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar	19 Feb 2026	0001432063

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EOLS	Common Stock	Award	$0	+94,913	+27%	$0.000000	451,734	17 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EOLS	Performance Restricted Stock Units	Award	$0	+94,913		$0.000000	94,913	17 Feb 2026	Common Stock	94,913		Direct	F2, F3
transaction	EOLS	Stock Option (Right to Buy)	Award	$0	+138,649		$0.000000	138,649	17 Feb 2026	Common Stock	138,649	$4.39	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon settlement of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).
F2	Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs.
F3	The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period.
F4	The shares subject to the option vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).

Remarks:

Chief Medical Officer and Head of R&D